Tags

Type your tag names separated by a space and hit enter

E-Cadherin complex protein expression and survival in ovarian carcinoma.
Gynecol Oncol. 2000 Dec; 79(3):362-71.GO

Abstract

OBJECTIVE

The aim of this study was to analyze the correlation between expression of E-cadherin complex proteins, epidermal growth factor receptor (EGFR), and c-erbB-2 and disease outcome in advanced-stage ovarian carcinomas.

METHODS

Sections from 75 primary ovarian carcinomas (=37) and metastatic lesions (=38) from 45 patients diagnosed with advanced-stage ovarian carcinoma (FIGO stage III-IV) were immunostained and evaluated for staining pattern, extent, and intensity. Patients were divided in two groups based on disease outcome. Long-term survivors (21 patients) and short-term survivors (24 patients) were defined using a double cutoff of 36 months for disease-free survival (DFS) and 60 months for overall survival (OS). Mean follow-up period was 70 months. The mean values for DFS and OS were 109 and 125 months for long-term survivors, as compared to 3 and 21 months for short-term survivors, respectively.

RESULTS

Comparison of all primary and metastatic lesions showed upregulation of gamma-catenin protein expression in the latter (P = 0.05). When segregated according to disease outcome, the expression of all studied proteins, with the exception of EGFR, was more diffuse in tumors of short-term survivors. The presence of cytoplasmic staining for c-erbB-2 was associated with poor survival in the entire cohort (P = 0.007), as well as in primary tumors alone (P = 0.003), in survival analysis. Similar results were seen in the evaluation of primary tumors for gamma-catenin (P = 0.002).

CONCLUSIONS

gamma-Catenin, and possibly c-erbB-2, are valid markers of poor survival in advanced-stage ovarian carcinoma.

Authors+Show Affiliations

Davidson B
Department of Pathology, The Norwegian Radium Hospital, Montebello, Oslo, N-0310, Norway. bend@ulrik.uio.no
Gotlieb WH
No affiliation info available
Ben-Baruch G
No affiliation info available
Nesland JM
No affiliation info available
Bryne M
No affiliation info available
Goldberg I
No affiliation info available
Kopolovic J
No affiliation info available
Berner A
No affiliation info available

MeSH

AdultAgedAged, 80 and overBiomarkers, TumorCadherinsCarcinomaCell MembraneCytoplasmDisease-Free SurvivalEpithelial CellsErbB ReceptorsFemaleFollow-Up StudiesHumansImmunohistochemistryMiddle AgedNeoplasm StagingOvarian NeoplasmsReceptor, ErbB-2Survival Analysis

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11104606

Citation

Davidson, B, et al. "E-Cadherin Complex Protein Expression and Survival in Ovarian Carcinoma." Gynecologic Oncology, vol. 79, no. 3, 2000, pp. 362-71.
Davidson B, Gotlieb WH, Ben-Baruch G, et al. E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol. 2000;79(3):362-71.
Davidson, B., Gotlieb, W. H., Ben-Baruch, G., Nesland, J. M., Bryne, M., Goldberg, I., Kopolovic, J., & Berner, A. (2000). E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecologic Oncology, 79(3), 362-71.
Davidson B, et al. E-Cadherin Complex Protein Expression and Survival in Ovarian Carcinoma. Gynecol Oncol. 2000;79(3):362-71. PubMed PMID: 11104606.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - E-Cadherin complex protein expression and survival in ovarian carcinoma. AU - Davidson,B, AU - Gotlieb,W H, AU - Ben-Baruch,G, AU - Nesland,J M, AU - Bryne,M, AU - Goldberg,I, AU - Kopolovic,J, AU - Berner,A, PY - 2000/12/6/pubmed PY - 2001/2/28/medline PY - 2000/12/6/entrez SP - 362 EP - 71 JF - Gynecologic oncology JO - Gynecol Oncol VL - 79 IS - 3 N2 - OBJECTIVE: The aim of this study was to analyze the correlation between expression of E-cadherin complex proteins, epidermal growth factor receptor (EGFR), and c-erbB-2 and disease outcome in advanced-stage ovarian carcinomas. METHODS: Sections from 75 primary ovarian carcinomas (=37) and metastatic lesions (=38) from 45 patients diagnosed with advanced-stage ovarian carcinoma (FIGO stage III-IV) were immunostained and evaluated for staining pattern, extent, and intensity. Patients were divided in two groups based on disease outcome. Long-term survivors (21 patients) and short-term survivors (24 patients) were defined using a double cutoff of 36 months for disease-free survival (DFS) and 60 months for overall survival (OS). Mean follow-up period was 70 months. The mean values for DFS and OS were 109 and 125 months for long-term survivors, as compared to 3 and 21 months for short-term survivors, respectively. RESULTS: Comparison of all primary and metastatic lesions showed upregulation of gamma-catenin protein expression in the latter (P = 0.05). When segregated according to disease outcome, the expression of all studied proteins, with the exception of EGFR, was more diffuse in tumors of short-term survivors. The presence of cytoplasmic staining for c-erbB-2 was associated with poor survival in the entire cohort (P = 0.007), as well as in primary tumors alone (P = 0.003), in survival analysis. Similar results were seen in the evaluation of primary tumors for gamma-catenin (P = 0.002). CONCLUSIONS: gamma-Catenin, and possibly c-erbB-2, are valid markers of poor survival in advanced-stage ovarian carcinoma. SN - 0090-8258 UR - https://www.unboundmedicine.com/medline/citation/11104606/E_Cadherin_complex_protein_expression_and_survival_in_ovarian_carcinoma_ DB - PRIME DP - Unbound Medicine ER -